Salix hits new high on Phase III IBS results
This article was originally published in Scrip
The past seven months have been good ones for Salix Pharmaceuticals, whose stock price has doubled since November, culminating in positive top-line Phase III results for Xifaxan (rifaximin) in the retreatment of irritable bowel syndrome with diarrhea (IBS-D) on 1 July.
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.